The Multiple Myeloma Hub spoke with Fredrik Schjesvold, Oslo University Hospital, Oslo, NO. We asked how belantamab mafodotin is currently used in clinical practice for multiple myeloma (MM).
In this interview, Schjesvold discusses the current use of belantamab mafodotin-based combinations in early relapsed/refractory MM, including their positioning alongside other available treatment options, such as B-cell maturation antigen (BCMA)-directed therapies. Schjesvold also outlines how toxicities, patient characteristics, and individual preferences influence treatment selection in routine clinical practice.
This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
","author_name":"Scientific Education Support"}